Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Malignant Neoplasm of Breast: early-phase trial registry

3 of 11 indexed Malignant Neoplasm of Breast trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Malignant Neoplasm of Breast: 11 US clinical trials tracked, 3 recruiting.

Malignant Neoplasm of Breast is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition malignant-neoplasm-of-breast

OPEN 3 | RECR 27% | LATE 0 | EARLY 6 | RANK #1577 | SPON 3

Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Malignant Neoplasm of Br (th…27%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Malignant Neoplasm of Breast

Malignant Neoplasm of Breast lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Neoplasm of Breast on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Neoplasm of Breast is recruiting below its size-band peers.

    3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Malignant Neoplasm of Breast research.

    M.D. Anderson Cancer Center accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Malignant Neoplasm of Breast trials plan to enrol fewer than 100 people.

    Median target enrolment is 34 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.

  4. Malignant Neoplasm of Breast research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 21

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 175 participants

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

National Cancer Institute (NCI)

NCT07067138

RECRUITING NA 122 participants

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Novian Health

NCT03463954

RECRUITING Phase 1 20 participants

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Calibr, a division of Scripps Research

NCT06878248

ACTIVE NOT RECRUITING Phase 1 90 participants

Selumetinib and Olaparib in Solid Tumors

M.D. Anderson Cancer Center

NCT03162627

ACTIVE NOT RECRUITING NA 62 participants

An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer

M.D. Anderson Cancer Center

NCT03429907

ACTIVE NOT RECRUITING Phase 1 34 participants

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

US Oncology Research

NCT03379428

ACTIVE NOT RECRUITING Phase 1 27 participants

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Washington University School of Medicine

NCT02204098

ACTIVE NOT RECRUITING Phase 1 18 participants

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

M.D. Anderson Cancer Center

NCT03435952

ACTIVE NOT RECRUITING 1 participants

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Pfizer

NCT06495164

COMPLETED NA 41 participants

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Washington University School of Medicine

NCT02891681

COMPLETED Phase 2 26 participants

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

HiberCell

NCT05159778

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1

Named interventions

Most-linked intervention names on Malignant Neoplasm of Breast records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound Device
1 trials
Imprime PGG Biological
1 trials
Mind-Body Exercises Behavioral
1 trials
Aromatase inhibitor Drug
1 trials
Clostridium Novyi-NT Biological
1 trials
Ibrutinib 420 mg Drug
1 trials
Ibrutinib 840 mg Drug
1 trials
Ibrutinib 560 mg Drug
1 trials

US sites by state

Facility locations filed on Malignant Neoplasm of Breast trials. A trial with sites in several states counts in each.

Texas 5 trials
New York 4 trials
Missouri 3 trials
Maryland 2 trials
Washington 1 trials
Virginia 1 trials
Tennessee 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Neoplasm of Breast page

11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Neoplasm of Breast condition card totals 11 registered trials; most-linked intervention Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.